CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• CVRx, Inc. has received a consensus recommendation of "Moderate Buy" from analysts, with an average 12-month target price of $14.00.
• Significant institutional investments have occurred, with Parkman Healthcare Partners increasing its stake by 33.5% and Balyasny Asset Management boosting its position by 65.5%.
• In its latest earnings report, CVRx reported a loss of ($0.57) EPS, missing the consensus estimate by $0.05, while generating revenue of $13.59 million against expectations of $13.22 million.

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.

Several brokerages have recently weighed in on CVRX. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 target price on shares of CVRx in a research note on Tuesday, August 5th. William Blair raised CVRx to a "strong-buy" rating in a research note on Monday, July 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CVRx in a research note on Saturday, September 27th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CVRX. Parkman Healthcare Partners LLC raised its stake in CVRx by 33.5% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company's stock valued at $15,037,000 after purchasing an additional 308,348 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in CVRx by 65.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company's stock valued at $3,967,000 after purchasing an additional 267,063 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in CVRx in the 1st quarter valued at $4,852,000. Geode Capital Management LLC raised its stake in CVRx by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company's stock valued at $2,249,000 after purchasing an additional 23,079 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in CVRx by 238.1% in the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company's stock valued at $2,058,000 after purchasing an additional 246,548 shares during the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Stock Performance

CVRx stock opened at $8.73 on Wednesday. The company has a current ratio of 11.99, a quick ratio of 10.78 and a debt-to-equity ratio of 0.85. CVRx has a 12 month low of $4.30 and a 12 month high of $18.55. The stock's 50 day simple moving average is $7.61 and its two-hundred day simple moving average is $7.45. The firm has a market cap of $228.29 million, a PE ratio of -4.16 and a beta of 1.26.

CVRx (NASDAQ:CVRX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.05). The company had revenue of $13.59 million during the quarter, compared to analysts' expectations of $13.22 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts anticipate that CVRx will post -1.91 earnings per share for the current year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.